• Fri frakt över 249 kr
  • •
  • Snabba leveranser
  • •
  • Billiga böcker
Kundservice

Du är på sajten för privatpersoner.

Företag, bibliotek eller offentlig verksamhet?

Du handlar på classic.bokus.com, där alla dina funktioner finns intakta.
Till classic.bokus.com
Bokus logotyp. Gå till startsidan.
  • Erbjudanden
  • Nyheter
  • Student
  • Topplistor
  • Barn & ungdom
  • Bokus Play
  • E-böcker
  • Pocketböcker
  • Spel & pussel

10% rabatt på allt med kod: NYSTART10 →

Sidfot

Mina sidor

    Hjälp

    • Kundservice
    • Vanliga frågor och svar
    • Frakt och leverans
    • Retur vid ångerrätt
    • Reklamera vara
    • Betalning
    • Köpvillkor
    • Allmänna villkor
    • Information om webbplatsens tillgänglighet

    Om Bokus

    • Om oss
    • Pressrum
    • För studenter
    • För företag
    • För bibliotek och offentlig verksamhet
    • För leverantörer
    • Hållbarhet

    Populärt

    • Aktuella erbjudanden
    • Presentkort
    • Studentlitteratur
    • Nya böcker
    • Topplistor
    • Signerade böcker
    • Engelska böcker

    Inspiration

    • Boktips
    • BookTok
    • Populära bokserier
    • Barnbokskaraktärer
    • Populära författare
    Logotyp för Bokus
    Följ oss på Facebook (extern länk)Följ oss på Instagram (extern länk)Följ oss på YouTube (extern länk)Följ oss på TikTok (extern länk)
    bokus @ CookiesAnpassa cookiesIntegritetspolicyKöpvillkor
    Till Citymail hemsida (extern länk)Till Budbee hemsida (extern länk)Till Postnord hemsida (extern länk)Till Schenker hemsida (extern länk)Till Early Bird hemsida (extern länk)Till Walleys hemsida (extern länk)
    1. Naturvetenskap och teknik
    2. Matematik och naturvetenskap
    3. Biologi
    4. Cellbiologi

    Gammadelta T cells in cancer immunotherapy

    AvIlan Bank,Dieter Kabelitz

    Inbunden, Engelska, 2024

    Del i serien Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy

    1 672 kr

    Kommande

    Beskrivning

    Gammadelta T cells in Cancer Immunotherapy shows how the potential of ?d T-cells can effectively be translated into clinical benefit in cancer immunotherapies. With a strong focus on finding alternatives to current T cell mediated cancer immunotherapies, the book can also be used as a baseline initial introduction to the field of gamma delta immunotherapy. In 13 chapters Gammadelta T cells in cancer immunotherapy describes different approaches to a specific model of gammadelta immunotherapy including ‘delta one T’ (DOT) and Allogeneic CAR. It describes the rationale for the use of gamma delta cells in immunotherapy, strategies, therapies, and cancer treatment. Gammadelta T cells in Cancer Immunotherapy answers the growing interest in the scientific and medical community in general immunotherapy and familiarizes end users with the basic biology of gammadelta T cells, the pre-clinical studies implying their utility in immunotherapy, and with the studies of clinical applications of different forms of gammadelta T cell immunotherapeutic. modalities. Contents will help both basic scientists and clinicians understand how to overcome hurdles inherent to current forms of CAR T cell immunotherapy

    Produktinformation

    • Utgivningsdatum:2024-08-01
    • Mått:191 x 234 x undefined mm
    • Format:Inbunden
    • Språk:Engelska
    • Serie:Breaking Tolerance to Anti-Cancer Cell-Mediated Immunotherapy
    • Förlag:Elsevier Science Publishing Co Inc
    • ISBN:9780443218798

    Utforska kategorier

    • Cellbiologi inom Naturvetenskap och teknik

    Mer om författaren

    Dr. Bank is a physician and immunologist, involved in research in the field of gammadelta T cells since 1986 . His scientific career henceforth included studies contributing to definition of the role of gammadelta T cells in autoimmune, infectious and malignant conditions in humans. Regarding the latter, his laboratory was among the first to show anti breast cancer activity of human gammadelta T cells, and later also their mechanisms of activity against glioblastoma. Most recently, his group participated in creation of anti lymphoma CAR (anti CD20) bearing human gammadelta T cells and reported preclinical efficacy., He has been editor of a topic on Gammadelta T cells in cancer including 11 papers published in Frontiers of Immunology and an active participant and organizer in the biannual gammadelta T cell meetings, and has been invited to chair the immunotherapy session in the upcoming meeting in Lisbon , 2023 Dieter Kabelitz is full professor at the University of Kiel, Germany, and Director of the Institute of Immunology. Dieter Kabelitz studied medicine in Freiburg and Munich, Germany. He was a post-doc in Uppsala/Sweden and at Rockefeller University, New York. In 1988, he was appointed Associate Professor for Cellular Immunology at the University of Heidelberg. From 1992 to 1999 he was Head of the Department of Immunology at the Paul-Ehrlich Institute in Langen, Germany. Since 1999 he is a full professor at the University of Kiel and Director of the Institute of Immunology. His scientific expertise is in the field of the functional characterization of human T cells with a special focus on ?? T cells. Current projects aim to explore the potential of human ?? T cells for the immunotherapy of cancer. He has published more than 360 papers listed in PubMed/Medline. Dieter Kabelitz was chairman of the Collaborative Research Center (SFB) 415 „Specificity and Pathophysiology of Signal Transduction Pathways“ funded at Kiel University by the German Research Foundation (DFG). He is a founding member and member of the Steering Committee of the DFG-funded Cluster of Excellence „Inflammation-at-Interfaces“. He was President of the German Society for Immunology (DGfI) in 2011 and 2012, and he is a Council member of the International Union of Immunological Societies (IUIS) and chair of the Education Committee (EDU) of IUIS.

    Innehållsförteckning

    • Chapter 1 The rationale for use of gd T cells in immunotherapy. Chapter 2 Tissue derived gammadelta T cells as vehicles for cancer immunotherapy Chapter 3 DOT-1 gammadelta T cell immunotherapeutic strategies. 4Chapter 4 Allogeneic Vg9Vd2 T cells treatment for solid tumors.Chapter 5 Gammadelta T cell receptor therapeutic reagents; mechanisms and applications Chapter 6 Immunotherapy based on bispecific antibodies targeting Vg9+ gd TCR and tumor antigens. Chapter 7 . Intratumoral Allogeneic gammadelta T cell therapy for glioblastoma multiforme Chapter 8 Allogeneic CAR expressing Vd1+ gammadelta T cells for lymphoma and hepatocellular carcinoma Chapter 9 Activating Monoclonal antibodies directed against butyrophilin ligands of Vg9Vd2+ gammadelta T cells for cancer immunotherapyChapter 10 Pro tumoral gammadelta T cells and their implication for immunotherapy. Chapter 11 Overcoming hurdles of gammadelta T cell immunotherapeuticsChapter 12 Increasing efficacy of gammadelta immunotherapy by targeted modulation of tumor phosphoantigens.Chapter 13 Summary and conclusions